Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.20.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Jul. 31, 2020
Jul. 31, 2019
Jul. 31, 2020
Jul. 31, 2019
Income Statement [Abstract]        
Revenue $ 250,000
Operating costs and expenses:        
Patent assertion expenses 166,250
Amortization of patents 41,875 418,750
Research and development expenses (including non-cash share-based compensation expenses of $394,842, $338,449, $1,250,497 and $2,567,294, respectively) 1,254,131 1,085,574 3,973,509 4,602,239
General and administrative expenses (including non-cash share-based compensation expenses of $646,957, $492,449, $1,922,722 and $2,335,218, respectively) 1,181,838 1,056,963 3,762,466 4,405,385
Impairment in carrying amount of patent asset 418,750
Total operating costs and expenses 2,435,969 2,184,412 7,735,975 10,011,374
Loss from operations (2,435,969) (2,184,412) (7,735,975) (9,761,374)
Other Expense (148,084) (148,084)
Interest income 7,266 18,364 32,707 53,783
Net loss (2,576,787) (2,166,048) (7,851,352) (9,707,591)
Less: Net loss attributable to noncontrolling interest (15,103) (26,020) (57,032) (148,030)
Net loss attributable to common shareholders $ (2,561,684) $ (2,140,028) $ (7,794,320) $ (9,559,561)
Net loss per common share attributable to common shareholders: Basic and diluted $ (0.11) $ (0.11) $ (0.36) $ (0.49)
Weighted average common shares outstanding: Basic and diluted 23,165,066 20,100,915 21,678,608 19,638,833